NCT03900442View on ClinicalTrials.gov

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

July 31, 2025

Study Completion Date

August 8, 2025

Conditions
Advanced CancerPTCL
Interventions
DRUG

PTX-100

Doses of 500 to 2000 mg/m2 will be administered.

Trial Locations (1)

3002

Epworth Healthcare, Melbourne

Sponsors
All Listed Sponsors
lead

Prescient Therapeutics, Ltd.

INDUSTRY

NCT03900442 - Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort | Biotech Hunter | Biotech Hunter